Search
Lofexidine
go.drugbank.com/drugs/DB04948ApprovedInvestigationalLofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. … [T210] Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine.
Synonyms: 2-(alpha-(2,6-Dichlorophenoxy)ethyl)2-imidazolineCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, MATE 1 InhibitorsRisperidone
go.drugbank.com/drugs/DB00734ApprovedInvestigational[L12885] It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone). … Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, P-glycoprotein substratesInternational brands: Risperidal M-TabMinaprine
go.drugbank.com/drugs/DB00805ApprovedMinaprine is a psychotropic drug which has proved to be effective in the treatment of various depressive states. Like most antidepressants minaprine antagonizes behavioral despair. … Minaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain.
Synonyms: 4-(2-((4-Methyl-6-phenyl-3-pyridazinyl)amino)ethyl)morpholine, N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamineCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 SubstratesPhenserine
go.drugbank.com/drugs/DB04892InvestigationalIf this is substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment for AD. … Phenserine is a next generation acetylcholinesterase (AChE) inhibitor indicated for the treatment of AD.
Categories: Heterocyclic Compounds, 2-RingAmineptine
go.drugbank.com/drugs/DB04836ApprovedIllicitWithdrawnThe Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeOndansetron
go.drugbank.com/drugs/DB00904ApprovedInvestigationalWithdrawn[L5221] The FDA withdrew its approval for the use of all intravenous drug products containing more than 16 mg of ondansetron hydrochloride in a single dose, due to a high risk of QT prolongation. … Having been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, P-glycoprotein substratesProducts: VONAU FLASH® 8 MG TABLETA DE DESINTEGRACION ORAL, VONAU FLASH® 4 MG TABLETA DE DESINTEGRACION ORALMenadione
go.drugbank.com/drugs/DB00170ApprovedNutraceuticalA synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.
Synonyms: Vitamin K 3, 2-Methyl-1,4-naphthochinonMixtures: LIBAVIT-K 20 MG AMPUL, 5 ADETMephentermine
go.drugbank.com/drugs/DB01365ApprovedWithdrawnA sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. … Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type dependence.
Categories: Adrenergic alpha-1 Receptor Agonists, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeLevodopa
go.drugbank.com/drugs/DB01235ApprovedInvestigationalLevodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. … Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after
Mixtures: MADOPAR 125 T, MADOPAR 125 TCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSalmeterol
go.drugbank.com/drugs/DB00938ApprovedInvestigational[A190459] Salmeterol was first described in the literature in 1988.[A190477] Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. … Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.
Mixtures: HOVID CLEFAN-S POWDER FOR INHALATION 50/250MCG, SALMETEROLO E FLUTICASONE SFCategories: Agents to Treat Airway Disease, Cytochrome P-450 Substrates